Research Insight
Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
Organovo Holdings, Inc announced that the U.S. FDA granted orphan drug designation for the Company’s treatment of alpha-1 antitrypsin deficiency (“A1AT”) with its 3D bioprinted liver therapeutic tissue. “We are extremely pleased to receive orphan designation...
Research Insight
Second Sartorius Research Xchange Forum Focuses On Regenerative Medicine and Cell Therapy
Promoting interdisciplinary exchange between science and industry on the topics of regenerative medicine and cell therapy: this is the objective Sartorius will be pursuing by hosting its second Research Xchange Forum on March 20 and 21, 2018, at Sartorius...
Research Insight
Mount Sinai Researchers Identify Novel Therapeutic Targets for Metastatic Melanoma, Path for New Drugs
Mount Sinai researchers have identified novel therapeutic targets for metastatic melanoma, according to a study published in Molecular Cell. The study focused on a gene called AMIGO2 and its partner, called PTK7. Scientists’ understanding of AMIGO2’s...
Research Insight
InVitria Announces New Media Formulation Service
InVitria, a division of Ventria Bioscience, has announced the launch of a new media formulation service at the international BIO-Europe conference in Berlin, Germany. Leveraging Ventria's proprietary ExpressTec technology, InVitria has developed and commercialized eight recombinant...
Articles
Auditory Therapy, Ototoxicity and GLP Compliance Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve?
The numbers are daunting – 15% of the global population suffers from hearing loss, including a significant number of children, teenagers, and the elderly. Hearing loss presents a growing public health problem, due to ageing and an urban way...
Articles
Nativis’ platform aims to transform disease treatment on a global scale – “a symphony of cures”
In late 2015, I was approached by the board of Nativis, Inc.to take on the leadership of the company, by then a 13-year-old “startup.”
I had already been on the board of directors for over two years and through first-hand...
Articles
Rivaroxaban plus aspirin improves outcomes in stable cardiovascular disease (COMPASS)
Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial presented today in a Hot Line – LBCT Session at ESC...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read